Paratek's top antibiotic fails to clear a key competitive hurdle in head-to-head studies

It’s rarely a good day when trial data comes back and one of the only things you can say about the results is that they told you what not to do.

But when Paratek Pharmaceuticals’ CEO looked over the top line results from two studies evaluating their Nuzyra antibiotic as a treatment for urinary tract infections, there was little else he could say. That and praise the trial design.